09 Dec 2021

Prof. Jackie Hunter
Board Director, BenevolentAI

Join BenevolentAI’s Board Director, Jackie Hunter, for a talk on our AI-augmented search for disease-modifying treatments for ALS

The complex aetiology and heterogeneity of neurodegenerative diseases, such as ALS, has proved a formidable barrier to the translation of basic research into effective treatments. With a rapidly ageing global population, the need to address this unmet medical need becomes ever more pressing. The exponential increase in biomedical data generation and research output, however, offers confidence that we are on the cusp of making substantial progress. This presentation will examine how the application of this technology is helping to enhance the mechanistic understanding of human disease, therapeutic target identification and uncover more effective disease-modifying treatments for ALS and other neurodegenerative diseases.

Register here 

Prof Jackie Hunter

Jackie Hunter is a Board Director of BenevolentAI. Jackie has over 30 years of experience in the bioscience research sector, working across academia and industry including leading neurology and gastrointestinal drug discovery and early clinical development for GlaxoSmithKline. She founded OI Pharma Partners in 2010 to support the life science sector in harnessing the power of open innovation and most recently was Chief Executive of the Biotechnology and Biological Sciences Research Council. She holds personal chairs from St George’s Hospital Medical School and Imperial College and serves on numerous advisory bodies and boards including the Technology Advisory Board of BP plc and A*Star Board Singapore. She also chairs the boards of Brainomix Ltd, Stevenage Bioscience Catalyst and the Sainsbury Laboratories Norwich.

Back to events